Elan sues Biogen Idec over alleged breach of Tysabri partnership
This article was originally published in Scrip
Executive Summary
Elan has filed a suit against Biogen Idec in federal court in New York, seeking to protect its interests in the multiple sclerosis drug Tysabri (natalizumab). It is seeking to prevent a possible termination of its partnership with Biogen Idec for the drug following Johnson & Johnson's proposed $1.5 billion investment in Elan.